Biovica International AB (publ)
BIOVIC-B.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$84.08M
Close$
Share Statistics
| Market cap | $84.08 Million |
|---|---|
| Enterprise Value | $38.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.3 |
| Beta | 1.15 |
| Outstanding Shares | 291,911,199 |
Return
| Return on Equity | -108.50% |
|---|---|
| Return on Assets | -80.19% |
| Return on Invested Capital | -100.82% |
Valuation & Multiples
| P/E Ratio | -1.22 |
|---|---|
| PEG | -9.14 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.6 |
| Enterprise Value to EBIT | -0.54 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 9, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$4.04 M
Average shareholder expectationNext Earnings Call
Expected Date
December 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$4.55 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biovica International AB (publ)
24 employees
CEO: Theis Kipling Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and pre...